Complement activation is associated with crescent formation in IgA nephropathy.


Journal

Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 01 12 2019
accepted: 18 03 2020
revised: 11 03 2020
pubmed: 18 4 2020
medline: 8 10 2020
entrez: 18 4 2020
Statut: ppublish

Résumé

IgA nephropathy (IgAN) is common chronic glomerulonephritis with variable prognosis, ranging from minor urinary abnormalities to end-stage renal disease. The revised Oxford classification of IgAN explains that cellular/fibrocellular crescents are associated with poor renal prognosis, proposing an extension to the MEST-C score. C3 immunofluorescent staining follows a distribution similar to IgA staining. Therefore, complement activation was reported to play a pivotal role in IgAN pathogenesis. This study included 132 IgAN patients diagnosed by renal biopsies. The clinical parameters at the time of the biopsies were obtained from patient data records. We classified the patients into C ≥ 1 and C0 groups, and compared clinical, light microscopic, and immunofluorescent features. In the C ≥ 1 group, 2 (1.5%) and 31 (23.5%) patients were assigned to C2 and C1, respectively. The remaining 99 patients (75%) were classified as C0. The C ≥ 1 group had lower average age and rate of hypertension, and higher score of urinary occult blood and E score. The C ≥ 1 group had significantly higher average immunofluorescence scores for IgA, C5b-9, mannose-associated serine protease (MASP) 1/3, MASP2, properdin, factor B, and kappa. The steroid use rate was significantly higher in the C ≥ 1 group. During the follow-up period of 2.90 years on average, the rate of renal dysfunction was not significantly different between groups. Crescent formation in IgAN was associated with activation of the lectin and alternative pathways. The C ≥ 1 group had significantly increased use of steroids, which probably caused comparable renal function during the follow-up period.

Identifiants

pubmed: 32300880
doi: 10.1007/s00428-020-02800-0
pii: 10.1007/s00428-020-02800-0
doi:

Substances chimiques

C3 protein, human 0
Complement C3 0
Complement Membrane Attack Complex 0
Immunoglobulin A 0
Immunoglobulin Light Chains 0
Properdin 11016-39-0
Complement System Proteins 9007-36-7
Mannose-Binding Protein-Associated Serine Proteases EC 3.4.21.-
Complement Factor B EC 3.4.21.47

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

565-572

Auteurs

Hiroe Itami (H)

Department of Diagnostic Pathology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, Japan. hritami1237@yahoo.co.jp.

Shigeo Hara (S)

Department of Diagnostic Pathology, Kobe City Medical Center General Hospital, Kobe, Japan.

Kenichi Samejima (K)

Department of Nephrology, Nara Medical University, Kashihara, Japan.

Hideo Tsushima (H)

Department of Nephrology, Nara Medical University, Kashihara, Japan.

Katsuhiko Morimoto (K)

Department of Nephrology, Nara Prefecture General Medical Center, Nara, Japan.

Keisuke Okamoto (K)

Department of Nephrology, Saiseikai Suita Hospital, Suita, Japan.

Takaaki Kosugi (T)

Department of Nephrology, Nara Prefectural Seiwa Medical Center, Sango, Japan.

Takahiro Kawano (T)

Department of Diabetes, Minami-Nara General Medical Center, Oyodo, Japan.

Kengo Fujiki (K)

Department of Diabetes, Minami-Nara General Medical Center, Oyodo, Japan.

Hiromichi Kitada (H)

Department of Internal Medicine, Saiseikai Chuwa Hospital, Sakurai, Japan.

Kinta Hatakeyama (K)

Department of Diagnostic Pathology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, Japan.

Kazuhiko Tsuruya (K)

Department of Nephrology, Nara Medical University, Kashihara, Japan.

Chiho Ohbayashi (C)

Department of Diagnostic Pathology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH